Loading…
← CockpitCompetitor Analysis › 003850.KS Boryung CorporationOpen in the cockpit ↗

Boryung Corporation003850.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major
Momentum leader 80
Mkt cap
$554M
US dollars, full cap
Free float
30%
of shares outstanding
$/day
$458,571
20-day average traded
Fwd P/E
11.3×
forward earnings
ROIC−WACC
-0.6 pp
WACC 5.2%
Hurdle
-16 pp
Req g minus delivered
Next earnings
82 days
8 Feb 2027
Close · KRW₩8,640
1D-0.6%
1W-1.8%
1M+3.1%
3M-5.8%
6M-12.6%
YTD-4.1%
1Y-3.6%
ATR %2.2%
52w lowhigh20.0% off high

What Boryung does

Employees: 1,645

Boryung at a glance

Size Boryung (003850.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $554M, the 325th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩8,640 on 18 Nov 2026.

Performance Over six months the shares fell 12.6%, against -20.3% for the median peer and -37.2% for the South Korea market (cap-weighted) — 6th highest of 19 in its peer set.

Growth Revenue grew 6.4% over the last twelve months (peer median +0.7%); the operating margin is 6.3% (peer median 6.8%).

Valuation It trades at 11.3× forward earnings against a peer median of 11.3× (5th cheapest of 10).

Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -16 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.6 points below its cost of capital (5.2% WACC).

Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026003850.KS 89Peer median 80
Six months, rebased to 100: Boryung against the median of its 20 peers (local-currency closes).

Boryung financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩1.09T₩1.02T₩1.02T₩860B₩760B
Revenue growth—0%+18%+13%—
Gross profit₩372B₩352B₩343B₩333B₩293B
EBITDA₩123B₩109B₩113B₩112B₩93.2B
Net income₩73.4B₩64.3B₩69.6B₩40.2B₩41.9B
Free cash flow₩114B₩112B₩67.7B₩27.2B₩7.54B
Capital expenditure₩316B₩29.1B₩20.0B₩23.3B₩123B
Total debt₩369B₩330B₩169B₩204B₩208B

Quarterly statements and history in the cockpit →

Boryung competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-20%0%ACRSZVRA4559002393002688688356MOREPENLABENTXALMSSENORES603222361322562157SUPRIYA003850.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Boryung is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%20×40×ZVRA4559002393002688688356SENORES36132157SUPRIYA003850.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Boryung is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%ZVRA45590023930026886883563613000919SUPRIYAEVONILE003850.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Boryung is the large dot.

Boryung competitors and peer comparison

How Boryung compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Boryung against its 20 peers (data as of 18 Nov 2026)
Measure003850.KSPeer medianRank in peer set
1-month return+3.1%-11.4%3rd highest of 20
6-month return-12.6%-20.3%6th highest of 19
Distance from 52-week high-20.0%-42.8%2nd highest of 20
Revenue growth (TTM)+6.4%+0.7%10th highest of 20
Operating margin6.3%6.8%9th lowest of 19
Forward P/E11.3×11.3×5th cheapest of 10
Growth the price implies (Req g, 7 yrs)-3.1%1.0%5th least demanding of 10
Growth delivered (Del g)+12.6%+9.7%3rd highest of 10
Hurdle (Req g minus delivered)-15.7 pp-8.7 pp4th least demanding of 10
ROIC minus cost of capital-0.6 pp-3.5 pp7th highest of 17
EV / EBITDA7.9×18.5×4th cheapest of 8
Net debt / EBITDA1.9×0.3×3rd most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Boryung 003850.KSSouth Korea$554M-13%+6%6%11.3×-3.1%+12.6%
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%n/an/an/a
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%11.3×-4.9%+51.6%
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%9.6×-12.3%+11.1%
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%9.0×-5.8%+4.1%
Jinhe Biotechnology 002688.SZChina$550M-19%+7%5%8.9×1.0%+9.7%
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%n/an/an/a
Jenkem Technology 688356.SSChina$563M-30%+52%11%30.2×36.4%+11.2%
Morepen Laboratories MOREPENLAB.NSIndia$542M+121%+30%11%n/an/an/a
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%n/an/an/a
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%32.2×n/an/a
Chimin Health Management 603222.SSChina$533M-31%+1%-28%n/an/an/a
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%10.2×-15.4%+2.8%
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%n/an/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%n/an/an/a
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%53.6×n/an/a
Electra Therapeutics ETRAUnited States$530Mn/an/an/an/an/an/a
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%n/a2.4%+5.0%
Supriya Lifescience SUPRIYA.NSIndia$529M-15%+23%26%36.2×28.2%+15.8%
Evonile Pharma EVONILE.NSIndia$529Mn/a-5%12%n/a49.3%-1.5%

Questions

Which companies are Boryung's closest peers?
The cockpit's peer set: Aclaris Therapeutics (ACRS), Zevra Therapeutics (ZVRA), Zeria Pharmaceutical (4559.T), Tianjin Lisheng Pharmaceutical (002393.SZ), Jinhe Biotechnology (002688.SZ), Zhong Zhu Healthcare (600568.SS), Jenkem Technology (688356.SS), Morepen Laboratories (MOREPENLAB.NS).
Is Boryung expensive compared with its peers?
On forward p/e it trades at 11.3× against a peer median of 11.3×, 5th cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -16 pp: the price already allows for a slowdown.
How has Boryung stock performed?
Over six months to 18 Nov 2026 the shares returned -12.6% against -20.3% for the median peer; over one year -3.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.